Abstract：
Radiation-induced skin damage (RID) is the most prevalent, significant side effect of radiotherapy (RT). Nearly 95% of patients experience moderate to severe skin reactions after receiving radiation therapy. However, criteria for acute radiation dermatitis (ARD) treatment remain unavailable. Topical agents with anti-inflammatory properties may protect the skin and facilitate tissue regeneration in patients with RID. Many of these topical agents function through nuclear factor kappa B pathway regulation. They either reduce the levels of inflammatory factors or elicit anti-inflammatory properties of their own, thus preventing oxidative stress and inflammatory responses and thus enabling RID prevention and management. Herein, we explore the 25 topical agents investigated for RID prevention and management thus far and evaluate their mechanisms of action. These agents include 11 natural agents, 3 miscellaneous agents, 9 topical nonsteroidal agents, and 2 topical corticosteroids.
摘要：
辐射诱发的皮肤损伤（RID）是最普遍的，放疗（RT）的显著副作用。近95%的患者在接受放射治疗后出现中度至重度皮肤反应。然而,目前尚无急性放射性皮炎(ARD)治疗标准.具有抗炎特性的局部药物可以保护RID患者的皮肤并促进组织再生。这些局部药物中的许多通过核因子κB途径调节起作用。它们要么降低炎症因子的水平，要么引发自身的抗炎特性，从而防止氧化应激和炎症反应，从而使RID的预防和管理。在这里，我们探讨了迄今为止研究的25种用于RID预防和管理的外用药物,并评估了其作用机制.这些药物包括11种天然药物，3个杂项代理商，9种局部非甾体药物，和2个局部皮质类固醇。
